[go: up one dir, main page]

DK3358011T3 - Peptid til inducering af regenerering af væv og anvendelse deraf - Google Patents

Peptid til inducering af regenerering af væv og anvendelse deraf Download PDF

Info

Publication number
DK3358011T3
DK3358011T3 DK18160112.1T DK18160112T DK3358011T3 DK 3358011 T3 DK3358011 T3 DK 3358011T3 DK 18160112 T DK18160112 T DK 18160112T DK 3358011 T3 DK3358011 T3 DK 3358011T3
Authority
DK
Denmark
Prior art keywords
time
tissue regeneration
induction tissue
induction
regeneration
Prior art date
Application number
DK18160112.1T
Other languages
English (en)
Inventor
Katsuto Tamai
Takehiko Yamazaki
Tsutomu Kanezaki
Shigeru Sakurai
Yukiko Noguchi
Mayumi Endo
Natsumi Hamabuchi
Kana Naito
Original Assignee
Univ Osaka
Stemrim Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka, Stemrim Inc filed Critical Univ Osaka
Application granted granted Critical
Publication of DK3358011T3 publication Critical patent/DK3358011T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
DK18160112.1T 2011-04-26 2012-04-03 Peptid til inducering af regenerering af væv og anvendelse deraf DK3358011T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011098270 2011-04-26
JP2011219454 2011-10-03
EP12777041.0A EP2703487B1 (en) 2011-04-26 2012-04-03 Peptide for inducing regeneration of tissue and use thereof

Publications (1)

Publication Number Publication Date
DK3358011T3 true DK3358011T3 (da) 2020-05-11

Family

ID=47071995

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12777041.0T DK2703487T3 (da) 2011-04-26 2012-04-03 Peptid til inducering af regenerering af væv og anvendelse deraf
DK18160112.1T DK3358011T3 (da) 2011-04-26 2012-04-03 Peptid til inducering af regenerering af væv og anvendelse deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12777041.0T DK2703487T3 (da) 2011-04-26 2012-04-03 Peptid til inducering af regenerering af væv og anvendelse deraf

Country Status (12)

Country Link
US (4) US10364276B2 (da)
EP (2) EP2703487B1 (da)
JP (6) JP6069191B2 (da)
KR (2) KR102113809B1 (da)
CN (3) CN114106139B (da)
AU (4) AU2012248676B2 (da)
CA (1) CA2834255C (da)
DK (2) DK2703487T3 (da)
ES (2) ES2684718T3 (da)
PL (2) PL2703487T3 (da)
PT (2) PT3358011T (da)
WO (1) WO2012147470A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
WO2011052668A1 (ja) 2009-10-28 2011-05-05 株式会社ジェノミックス 骨髄間葉系および/または多能性幹細胞の血中動員による組織再生促進剤
RU2649069C2 (ru) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
AU2013335684B2 (en) * 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
EP3003290B1 (en) * 2013-06-05 2021-03-10 AgeX Therapeutics, Inc. Compositions for use in the treatment of wounds in mammalian species
JP6841507B2 (ja) 2015-05-07 2021-03-10 ユニヴァーシティ オブ サウス フロリダ アンジェルマン症候群の遺伝子治療法のための組み換えｕｂｅ３ａ遺伝子
EP3387112A4 (en) 2015-12-07 2019-08-21 BioTime, Inc. METHOD FOR RECONNECTING BROWN FAT CELLS DERIVED FROM VARIOUS PLURIPOTENT STEM CELLS
CN106995796A (zh) * 2016-01-26 2017-08-01 李建业 基于细胞因子的细胞处理方法、试剂盒及冻干粉
US10864253B2 (en) 2016-04-29 2020-12-15 Araim Pharmaceuticals, Inc. Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
US11065286B2 (en) 2016-09-21 2021-07-20 Stephen H. Thorne High mobility group box I mutant
BR112019014921A2 (pt) * 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
RU2019134382A (ru) 2017-04-07 2021-05-07 Стемрим Инк. Лекарственное средство для лечения фиброзного заболевания
BR112019021230A2 (pt) * 2017-04-25 2020-06-02 Shionogi & Co., Ltd. Peptídeos, composições que os compreende e uso dos mesmos
WO2019107530A1 (ja) 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
JPWO2019107566A1 (ja) * 2017-12-01 2020-12-03 株式会社ステムリム 外胚葉性間葉系幹細胞およびその製造方法
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
BR112021005982A2 (pt) 2018-10-05 2021-06-29 StemRIM Inc. peptídeo possuindo atividade de mobilização de células-tronco mesenquimais
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
MX2021004758A (es) 2018-10-25 2021-08-24 Univ Osaka Agente terapeutico para el trastorno de cartilago.
US20220175940A1 (en) * 2019-03-26 2022-06-09 Niigata University Peptide and use thereof
CN109957015A (zh) * 2019-04-01 2019-07-02 中国人民解放军海军军医大学国家肝癌科学中心 一种hmgb1封闭性抗体的制备方法及其应用
WO2021094983A1 (en) * 2019-11-12 2021-05-20 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
WO2021201260A1 (ja) * 2020-04-03 2021-10-07 株式会社ステムリム 間葉系幹細胞の動員活性を有するペプチド
JP7750489B2 (ja) 2020-04-20 2025-10-07 塩野義製薬株式会社 Ｈｍｇｂ１部分ペプチドを含有する製剤
EP4138878A4 (en) * 2020-04-22 2024-03-20 Chulalongkorn University A composition and a method of rejuvenating dna and preventing dna damage
EP4257703A4 (en) * 2020-12-07 2025-06-04 Samsung Life Public Welfare Foundation Method for selecting mesenchymal stem cells with improved self-sustainability and thereby selected mesenchymal stem cells
WO2022243932A1 (en) * 2021-05-19 2022-11-24 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
CA3233234A1 (en) 2021-09-30 2023-04-06 Katsuto Tamai Drug for treating fatty liver and nonalcoholic steatohepatitis
CN116983471B (zh) * 2023-06-07 2024-03-08 华中科技大学同济医学院附属协和医院 一种基于α-螺旋双亲性多肽的超分子共组装凝胶的制备方法及应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5238680B2 (da) 1972-12-27 1977-09-30
US4732155A (en) 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5661127A (en) 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
JP3018313B2 (ja) 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
WO2001008683A1 (en) 1999-07-28 2001-02-08 The Board Of Trustees Of The Leland Stanford Junior University Nicotine receptor agonists in stem cell and progenitor cell recruitment
WO2001032129A2 (en) 1999-11-05 2001-05-10 Gerigene Medical Corporation Augmentation and repair of age-related soft tissue defects
EP1114862A3 (de) 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
JP3421741B2 (ja) 2000-05-18 2003-06-30 筑波大学長 人工骨髄、血球細胞の増殖方法
ITMI20010562A1 (it) 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
EP1390058A2 (en) 2001-04-30 2004-02-25 Switch Biotech Aktiengesellschaft Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
DE10121254A1 (de) 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
US20030060410A1 (en) 2001-05-15 2003-03-27 North Shore Long Island Jewish Research Institute Use of HMG fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US20040265971A1 (en) 2001-11-19 2004-12-30 Hidetaka Sato Drug mobilizing pluripotent stem cells from tissue into peripheral blood
EP2305276A3 (en) 2001-12-07 2011-09-21 Cytori Therapeutics, Inc. Processed lipoaspirate cells for use in therapy
FR2833609B1 (fr) 2001-12-19 2004-12-03 Natural Implant Dispositif de prelevement cellulaire ou tissulaire en phase active et utilisations
ATE424416T1 (de) * 2002-07-03 2009-03-15 San Raffaele Centro Fond Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
WO2004004770A1 (en) 2002-07-05 2004-01-15 Universite Laval Chemotactic factor inhibitor for modulating inflammatory reactions
GB0226251D0 (en) 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
EP1569684A4 (en) 2002-11-20 2006-08-02 Critical Therapeutics Inc USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
CA2512512A1 (en) 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of hmgb, hmgn, hmga proteins
WO2004075855A2 (en) 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
US7632802B2 (en) 2003-03-28 2009-12-15 UNIVERSITé LAVAL S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
CN1193092C (zh) 2003-03-28 2005-03-16 浙江大学 骨髓间充质干细胞分离和体外扩增培养方法
US20090069227A9 (en) 2003-04-29 2009-03-12 Capogrossi Maurizio C Use of HMGB1 to promote stem cell migration and/or proliferation
US20050014255A1 (en) 2003-05-29 2005-01-20 Board Of Regents, The University Of Texas System Stem cells for clinical and commercial uses
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
CA2882022A1 (en) * 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
ITRM20040058A1 (it) 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
CA2574548A1 (en) 2004-07-20 2006-01-26 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 for wound healing
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
MX2007002557A (es) 2004-09-03 2007-10-10 Creabilis Therapeutics Spa Uso de polipeptidos obtenidos a traves de mutaciones sistematicas de aminoacidos unicos de bloque-a humano y no humano de hmgb1 para prevenir y/o antagonizar las patologias inducidas por hmgb1.
AU2005333602B2 (en) * 2004-10-22 2012-04-12 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
KR100593397B1 (ko) 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
ITRM20050032A1 (it) 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
US9782439B2 (en) 2005-01-27 2017-10-10 Japan Health Sciences Foundation Cell sheet containing mesenchymal stem cells
KR101319135B1 (ko) 2005-03-23 2013-10-17 바이오세이프 쏘시에떼아노님 재생 의약에서 성체 줄기 세포를 비롯한 세포 부분집합의 수집, 처리, 이식을 위한 통합된 기계 장치
KR100775958B1 (ko) * 2005-03-30 2007-11-13 김정문 조직재생 기능을 가지는 비활성 폴리펩티드 및 그 제조방법
WO2006114805A2 (en) 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
US20100280493A1 (en) 2005-06-23 2010-11-04 Asha Nayak Methods and Systems for Treating Injured Cardiac Tissue
WO2007015546A1 (ja) 2005-08-04 2007-02-08 Genomix Co., Ltd 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法
WO2007031100A1 (en) 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
WO2007061762A2 (en) * 2005-11-18 2007-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt And Human Services Non-viral gene delivery complex
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
JP4982739B2 (ja) 2006-06-01 2012-07-25 国立大学法人 東京医科歯科大学 ポリグルタミン病の予防・治療剤
EP2046834B9 (en) 2006-08-11 2013-04-10 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
PL2068935T3 (pl) 2006-09-15 2011-11-30 Creabilis Therapeutics S R L Polimerowe koniugaty BOX-A HMGB1 i warianty HMGB1
DK2068935T3 (da) * 2006-09-15 2011-08-01 Creabilis Therapeutics S R L Polymerkonjugater af box-A af HMBG1 og boks-A-varianter af HMBG1
CN101374538A (zh) 2006-10-30 2009-02-25 吉诺米克斯股份有限公司 损伤组织的功能再生促进药物
CA2629652A1 (en) 2007-04-24 2008-10-24 Yaojiong Wu Compositions for preventing or treating skin defects and methods of use thereof
US8114668B2 (en) 2007-05-14 2012-02-14 Cardiac Pacemakers, Inc. Composition for cold storage of stem cells
JP5660889B2 (ja) 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
RU2010148785A (ru) 2008-04-30 2012-06-10 Дженомикс Ко., Лтд. (Jp) Фармацевтическое средство для стимуляции функциональной регенерации поврежденной ткани
WO2011046570A1 (en) 2009-10-16 2011-04-21 The University Of Medicine And Dentistry Of New Jersey Method for treating chronic nerve tissue injury using a cell therapy strategy
WO2011052668A1 (ja) 2009-10-28 2011-05-05 株式会社ジェノミックス 骨髄間葉系および/または多能性幹細胞の血中動員による組織再生促進剤
CN102443064A (zh) 2011-11-03 2012-05-09 刘誉 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用
AU2013335684B2 (en) 2012-10-25 2017-06-29 Osaka University Novel method for treating cardiac infarction using HMGB1 fragment
RU2649069C2 (ru) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1

Also Published As

Publication number Publication date
PL2703487T3 (pl) 2019-03-29
KR20190073610A (ko) 2019-06-26
KR102113809B1 (ko) 2020-05-21
ES2788394T3 (es) 2020-10-21
PL3358011T3 (pl) 2020-08-24
AU2012248676A1 (en) 2013-11-21
JP2017078067A (ja) 2017-04-27
US20230212241A1 (en) 2023-07-06
CN107188948A (zh) 2017-09-22
JP2020058344A (ja) 2020-04-16
WO2012147470A1 (ja) 2012-11-01
CA2834255C (en) 2021-11-02
EP3358011B1 (en) 2020-03-04
JP2018138049A (ja) 2018-09-06
EP3358011A1 (en) 2018-08-08
US20180072785A1 (en) 2018-03-15
CN103687946A (zh) 2014-03-26
AU2012248676B2 (en) 2017-04-20
CN103687946B (zh) 2017-05-03
HK1258536A1 (en) 2019-11-15
US10550165B2 (en) 2020-02-04
AU2017203644B9 (en) 2019-06-06
JP2021191271A (ja) 2021-12-16
EP2703487B1 (en) 2018-06-27
AU2017203644A1 (en) 2017-06-15
JP6336549B2 (ja) 2018-06-06
CN107188948B (zh) 2021-11-30
AU2022201894A1 (en) 2022-04-07
CN114106139B (zh) 2024-08-30
US10364276B2 (en) 2019-07-30
JP6069191B2 (ja) 2017-02-01
JPWO2012147470A1 (ja) 2015-02-23
AU2017203644B2 (en) 2019-05-16
AU2019210647A1 (en) 2019-08-22
JP6603964B2 (ja) 2019-11-13
KR20140036202A (ko) 2014-03-25
CA2834255A1 (en) 2012-11-01
AU2019210647B2 (en) 2021-12-23
DK2703487T3 (da) 2018-09-10
US20200369736A1 (en) 2020-11-26
EP2703487A4 (en) 2014-11-12
CN114106139A (zh) 2022-03-01
EP2703487A1 (en) 2014-03-05
AU2022201894B2 (en) 2024-10-10
JP2023106525A (ja) 2023-08-01
ES2684718T3 (es) 2018-10-04
US20140206619A1 (en) 2014-07-24
PT3358011T (pt) 2020-04-23
KR101992807B1 (ko) 2019-06-26
PT2703487T (pt) 2018-10-11

Similar Documents

Publication Publication Date Title
DK3358011T3 (da) Peptid til inducering af regenerering af væv og anvendelse deraf
IL285985A (en) Therapeutic nuclease compositions and methods
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK2734128T3 (da) Kirurgisk hentningsindretning med halvstift udtrækkelig og sammenklappelig kurv
DK3045187T3 (da) Injektor og fremgangsmåde til samling
PL3863288T3 (pl) Sposoby intra-predykcji i środek nośnikowy
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
DK2675827T3 (da) Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
EP2760407A4 (en) DISPOSABLE CLOTHING ITEMS
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
EP2739695A4 (en) ADHESIVES AND THEIR USE
DK3466969T3 (da) Lipoproteinkomplekser og fremstilling og anvendelse deraf
DK3269386T3 (da) Aluminiumforbindelser til anvendelse inden for behandling og i vacciner
IL232262A (en) Therapeutic agents and uses thereof
CO7020866A2 (es) Péptidos terapéuticos
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
DK2552434T3 (da) Peptider og anvendelse deraf
DK3197164T3 (da) Afkodningsanordning og afkodningsfremgangsmåde
HRP20171579T8 (hr) Antigljivična sredstva i njihova upotreba
PL2928905T3 (pl) Sposób oczyszczania białek terapeutycznych
DK3392252T3 (da) Pyrimido-pyridazinonforbindelser og deres anvendelse
DK3326642T3 (da) Langtidsvirkende koagulationsfaktorer og brugen deraf
DK2883954T3 (da) Peptidbibliotek og anvendelse deraf
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf